Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 1/2016

01-01-2016 | Guest Editorial

A SWOT Analysis of the Updated National HIV/AIDS Strategy for the U.S., 2015–2020

Authors: David R. Holtgrave, Robert Greenwald

Published in: AIDS and Behavior | Issue 1/2016

Login to get access

Abstract

In July 2015, President Barack Obama released an updated National HIV/AIDS Strategy (NHAS) for the United States to guide HIV efforts through the year 2020. A federal action plan to accompany the updated NHAS will be released in December 2015. In this editorial, we offer a strengths, weaknesses, opportunities and threats analysis with the aim of increasing discussion of ways to truly fulfill the promise of the updated NHAS and to address barriers that may thwart it from achieving its full potential.
Literature
1.
2.
Holtgrave DR, Hall HI, Wehrmeyer L, Maulsby C. Costs, consequences and feasibility of strategies for achieving the goals of the National HIV/AIDS Strategy in the United States: a closing window for success? AIDS Beh. 2012;16(6):1365–72.CrossRef
3.
Holtgrave DR. Achieving and advancing the goals of the National HIV/AIDS Strategy for the United States. AIDS Behav. 2015;19(2):211–3.PubMedCrossRef
4.
Holtgrave DR. Development of year 2020 goals for the National HIV/AIDS Strategy for the United States. AIDS Behav. 2014;18(4):638–43.PubMedCrossRef
5.
6.
7.
8.
Helms MM, Nixon J. Exploring SWOT analysis—where are we now? A review of academic research from the last decade. J Strategy Manag. 2010;3(3):215–51.CrossRef
9.
10.
Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):390–409.PubMedCrossRef
11.
12.
13.
14.
Cremin I, Hallett TB. Estimating the range of potential epidemiological impact of pre-exposure prophylaxis: run-away success or run-away failure? AIDS. 2015;29(6):733–8.PubMedCrossRef
15.
Kessler J, Myers JE, Nucifora KA, Mensah N, Toohey C, Khademi A, Cutler B, Braithwaite S. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. AIDS. 2014;28(18):2683–91.PubMedCrossRef
16.
Juusola JL, Brandeau ML, Owens DK, Bedavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541–50.PubMedPubMedCentralCrossRef
17.
Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17(5):1632–6.PubMedCrossRef
18.
19.
20.
21.
22.
23.
24.
Centers for Disease Control and Prevention. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. Morb Mortal Wkly Rep. 2015;64(16):443–4.
25.
Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB, Sansom SL. Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64(2):e15–8.PubMedCrossRef
Metadata
Title
A SWOT Analysis of the Updated National HIV/AIDS Strategy for the U.S., 2015–2020
Authors
David R. Holtgrave
Robert Greenwald
Publication date
01-01-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1193-9

Other articles of this Issue 1/2016

AIDS and Behavior 1/2016 Go to the issue

Original Paper

HIV Stigma in Prisons and Jails: Results from a Staff Survey

Original Paper

Stigma Toward Men Who Have Sex with Men Among Future Healthcare Providers in Malaysia: Would More Interpersonal Contact Reduce Prejudice?

Original Paper

Do People Know I’m Poz?: Factors Associated with Knowledge of Serostatus Among HIV-Positive African Americans’ Social Network Members

Original Paper

The ‘Fears’ of Disclosing HIV Status to Sexual Partners: A Mixed Methods Study in a Counseling Setting in Ghana

Original Paper

Impact Evaluation of a Policy Intervention for HIV Prevention in Washington, DC

Brief Report

Proximate Context of HIV Stigma and Its Association with HIV Testing in Sierra Leone: A Population-Based Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits